



Enabling Discovery in Life Science®

MMP-13 Colorimetric Drug Discovery Kit

Designed to screen MMP-13 inhibitors using a thiopeptide as a chromogenic substrate.

Instruction Manual

BML-AK412

For research use only

BACKGROUND

Matrix metalloproteinase-13 (MMP-13, collagenase-3) is a member of the MMP family of extracellular proteases. These enzymes play a role in many normal and disease states by virtue of their broad substrate specificities¹. Targets of MMP-13 include collagen, gelatin, aggrecan, plasminogen, and CXCL12^{1,2}. MMP-13 is secreted as a 60 kDa proenzyme (as measured by SDS-PAGE), and activated by cleavage to 48 kDa and below^{3,4}. MMP-13 is an important target for inhibitor screening due to its involvement in diseases such as cancer and arthritis⁵⁻⁷.

The *MMP-13 Colorimetric Drug Discovery Kit* is a complete assay system designed to screen MMP-13 inhibitors using a thiopeptide as a chromogenic substrate (Ac-PLG-[2-mercapto-4-methyl-pentanoyl]-LG-OC₂H₅)^{8,9}. The MMP cleavage site peptide bond is replaced by a thioester bond in the thiopeptide. Hydrolysis of this bond by an MMP produces a sulfhydryl group, which reacts with DTNB [5,5'-dithiobis(2-nitrobenzoic acid), Ellman's reagent] to form 2-nitro-5-thiobenzoic acid, which can be detected by its absorbance at 412 nm ($\epsilon=13,600 \text{ M}^{-1}\text{cm}^{-1}$ at pH 6.0 and above¹⁰). The assays are performed in a convenient 96-well microplate format. The kit is useful to screen inhibitors of MMP-13, a potential therapeutic target. An inhibitor, NNGH¹¹, is also included as a prototypic control inhibitor. Thiol inhibitors should not be used with this kit, as they may interfere with the colorimetric assay.

REFERENCES:

1. L.J. McCawley and L.M. Matrisian *Curr. Opin. Cell Biol.* 2001 **13** 534
2. M. Egeblad and Z. Werb *Nat. Rev. Cancer* 2002 **2** 163
3. S. Cowell *et al. Biochem. J.* 1998 **331** 453
4. Knäuper *et al. J. Biol. Chem.* 1996 **271** 1544
5. Pendás A.M. *et al. Clin. Chim. Acta* 2000 **291** 137
6. W.G. Stetler-Stevenson and A.E. Yu *Semin. Cancer Biol.* 2001 **11** 143
7. J.A. Mengshol *et al. Arthritis Rheum.* 2002 **46** 13
8. H. Weingarten and J. Feder *Anal. Biochem.* 1985 **147** 437
9. H. Weingarten *et al. Biochemistry* 1985 **24** 6730
10. L. Yu and E.A. Dennis *Methods Enzymol.* 1991 **197** 65
11. L.J. MacPherson *et al. J. Med. Chem.* 1997 **40** 2525

PLEASE READ ENTIRE BOOKLET BEFORE PROCEEDING WITH THE ASSAY. CAREFULLY NOTE THE HANDLING AND STORAGE CONDITIONS OF EACH KIT COMPONENT. PLEASE CONTACT ENZO LIFE SCIENCES TECHNICAL SERVICES FOR ASSISTANCE IF NECESSARY.

COMPONENTS OF KIT AK-412

BML-SE246-9090 MMP-13 ENZYME (HUMAN, RECOMBINANT)

FORM: *E. coli* recombinant human MMP-13 catalytic domain (calculated MW 20.4 kDa), 3.45 U/ μ L. One U=100 pmol/min@ 37°C, 100 μ M thiopeptide P125.

STORAGE: -80°C; Avoid freeze/thaw cycles

QUANTITY: 180 U

BML-P125-9090 MMP SUBSTRATE (chromogenic; MW=655.9)

FORM: 25 mM (16.4 mg/mL) in DMSO

STORAGE: -20°C

QUANTITY: 50 μ L

BML-PI115-9090 INHIBITOR (NNGH; MW=316.4)

FORM: 1.3 mM in DMSO

STORAGE: -20°C

QUANTITY: 50 μ L

BML-KI173-0020 ASSAY BUFFER

50 mM HEPES, 10 mM CaCl₂, 0.05% Brij-35, 1 mM DTNB, pH7.5

STORAGE: -20°C

QUANTITY: 20 mL

80-2404 ½ VOLUME CLEAR 96-WELL MICROPLATE

STORAGE: Ambient

OTHER MATERIALS REQUIRED

Microplate reader capable of measuring A₄₁₂ to ≥ 3 -decimal accuracy.

Pipetman or multi-channel pipetman capable of pipetting 10-100 μ L accurately (note: reagents can be diluted to increase the minimal pipetting volume to >10 μ L).

Ice bucket to keep reagents cold until use.

Water bath or incubator for component temperature equilibration.

EXPERIMENTAL METHODS

Note on storage: Store all components except the microtiter plate at -80°C for the highest stability. Components with storage temperatures other than -80°C can be stored at the temperature listed OR at -80°C . The MMP-13 enzyme should be handled carefully in order to retain maximal enzymatic activity. It is stable, in diluted or concentrated form, for several hours on ice. As supplied, MMP-13 enzyme is stable for at least 5 freeze/thaw cycles. To minimize the number of freeze/thaw cycles, aliquot the MMP-13 into separate tubes and store at -80°C . When setting up the assay, do not maintain diluted components at reaction temperature (e.g. 37°C) for an extended period of time prior to running the assay.

To start assay:

1. Briefly warm kit components P125-9090 and PI115-9090 to RT to thaw DMSO.
2. Dilute inhibitor (NNGH, PI115-9090) 1/200 in assay buffer KI173 as follows. Add 1 μL inhibitor into 200 μL assay buffer, in a separate tube. Warm to reaction temperature (e.g. 37°C).
3. Dilute substrate P125-9090 1/25 in assay buffer to required total volume (10 μL are needed per well). For example, for 15 wells dilute 6.4 μL P125-9090 into 153.6 μL assay buffer, in a separate tube. Warm to reaction temperature (e.g. 37°C).
4. Dilute MMP-13 enzyme 1/50 in assay buffer to required total volume (20 μL are needed per well). Warm to reaction temperature (e.g. 37°C) shortly before assay.
5. Pipet assay buffer into each desired well of the 1/2 volume microplate as follows:
Blank (no MMP-13) = 90 μL Assay Buffer
Control (no inhibitor) = 70 μL Assay Buffer
Inhibitor NNGH=50 μL Assay Buffer
Test inhibitor=varies (see Table 1, below)
6. Allow microplate to equilibrate to assay temperature (e.g. 37°C).
7. Add 20 μL MMP-13 (diluted in step 4) to the control, inhibitor NNGH, and test inhibitor wells. Final amount of MMP-13 will be 1.38 U per well (13.8 mU/ μL). Remember to **not** add MMP-13 to the blanks!
8. Add 20 μL NNGH inhibitor (diluted in step 2) to the inhibitor NNGH wells only! Final inhibitor concentration=1.3 μM . See Figure 2 for inhibition of MMP-13 by NNGH.
9. Add desired volume of test inhibitor to appropriate wells. See Table 1, below.
10. Incubate plate for 30-60 minutes at reaction temperature (e.g. 37°C) to allow inhibitor/enzyme interaction.

11. Start reaction by the addition of 10 μL P125-9090 substrate (diluted and equilibrated to reaction temperature in step 3). Final substrate concentration=100 μM .
12. Continuously read plates at $A_{412\text{nm}}$ in a microplate reader. Record data at 1 min. time intervals for 10 to 20 min.
13. Perform data analysis (see below).

NOTE: Retain microplate for future use of unused wells.

TABLE 1. Example of Samples.

Sample	Assay buffer	MMP-13 (69 mU/ μL)	Inhibitor (6.5 μM)	Substrate (1 mM)	Total Volume
Blank	90 μL	0	0	10 μL	100 μL
Control	70 μL	20 μL	0	10 μL	100 μL
Inhibitor NNGH	50 μL	20 μL	20 μL	10 μL	100 μL
Test inhibitor*	X μL	20 μL	Y μL	10 μL	100 μL

*Test inhibitor is the experimental inhibitor. Dissolve/dilute inhibitor into assay buffer and add to appropriate wells at desired volume "Y". Adjust volume "X" to bring the total volume to 100 μL .

Example of plate:

well#	sample
A1	Blank
B1	Blank
C1	Control
D1	Control
E1	Inhibitor NNGH
F1	Inhibitor NNGH
G1	Test inhibitor
H1	Test inhibitor

DATA ANALYSIS

Plotting


1. Plot data as OD versus time for each sample (see Fig. 1).
2. Determine the range of time points during which the reaction is linear. Typically, points from 1 to 10 min are sufficient.
3. Obtain the reaction velocity (**V**) in OD/min: determine the slope of a line fit to the linear portion of the data plot using an appropriate routine.
4. Average the slopes of duplicate samples.

Data Reduction

5. *If the blank has a significant slope, subtract this number from all samples.*
6. To determine inhibitor % remaining activity:


$$\text{Inhibitor \% activity remaining} = (\mathbf{V} \text{ inhibitor} / \mathbf{V} \text{ control}) \times 100$$

See Figure 2 for example.



Slope= $V=7.00E-03$ OD/min


Figure 2. Example of inhibitor data:



control slope = $7.00E-03$ OD/min

inhibitor (100 nM) slope = $4.50E-04$ OD/min

inhibitor % activity remaining = $(4.50E-04/7.00E-03) \times 100 = 6.4\%$



7. To find the activity of the samples expressed as mol substrate/min, employ the following equation:

$$X \text{ mol substrate/min} = (V \times \text{vol.}) / (\epsilon \times \ell)$$

Where **V** is reaction velocity in OD/min, vol. is the reaction volume in liters, ϵ is the extinction coefficient of the reaction product (2-nitro-5-thiobenzoic acid) ($13,600 \text{ M}^{-1}\text{cm}^{-1}$), and ℓ is the path length of light through the sample in cm (for 100 μL in the supplied microplate, ℓ is 0.5 cm).

Note: The above equation determines enzyme activity in terms of moles of thiopeptolide substrate P125 converted per minute. Under these conditions, the secondary substrate DTNB is saturating, and the velocity of DTNB conversion to 2-nitro-5-thiobenzoic acid is not rate-limiting.


See Figure 3 for activity and kinetic calculations.

Figure 3. Example calculation for activity:

Activity of a control sample =

$$(9.40\text{E-}03\text{OD/min} \times 1\text{E-}04\text{L}) / (13,600\text{M}^{-1}\text{cm}^{-1} \times 0.5\text{cm}) = 1.38\text{E-}10 \text{ mol/L/min at } 37^\circ\text{C, } 100 \mu\text{M thiopeptolide P125}$$

Example graph for K_m and V_{max} determination:



$$K_m = 65.3 \mu\text{M}$$

$$V_{max} = 3.81 \text{ pmol/L/sec}$$

USE FOR RESEARCH PURPOSES ONLY

Unless otherwise specified expressly on the packaging, all products sold hereunder are intended for and may be used for research purposes only and may not be used for food, drug, cosmetic or household use or for the diagnosis or treatment of human beings. Purchase does not include any right or license to use, develop or otherwise exploit these products commercially. Any commercial use, development or exploitation of these products or development using these products without the express written authorization of Enzo Life Sciences, Inc. is strictly prohibited. Buyer assumes all risk and liability for the use and/or results obtained by the use of the products covered by this invoice whether used singularly or in combination with other products.

LIMITED WARRANTY; DISCLAIMER OF WARRANTIES

These products are offered under a limited warranty. The products are guaranteed to meet all appropriate specifications described in the package insert at the time of shipment. Enzo Life Sciences' sole obligation is to replace the product to the extent of the purchasing price. All claims must be made to Enzo Life Sciences, Inc., within five (5) days of receipt of order. THIS WARRANTY IS EXPRESSLY IN LIEU OF ANY OTHER WARRANTIES OR LIABILITIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF OTHERS, AND ALL SUCH WARRANTIES (AND ANY OTHER WARRANTIES IMPLIED BY LAW) ARE EXPRESSLY DISCLAIMED.

TRADEMARKS AND PATENTS

Several Enzo Life Sciences products and product applications are covered by US and foreign patents and patents pending.

www.enzolifesciences.com
Enabling Discovery in Life Science®

Global Headquarters

Enzo Life Sciences Inc.

10 Executive Blvd
Farmingdale, NY 11735
(p) 1-800-942-0430
(f) 1-631-694-7501
(e) info-usa@enzolifesciences.com

Enzo Life Sciences (ELS) AG

Industriestrasse 17, Postfach
CH-4415 Lause / Switzerland
(p) +41/0 61 926 89 89
(f) +41/0 61 926 89 79
(e) info-ch@enzolifesciences.com

Please visit our website at www.enzolifesciences.com for additional contact information.